GLSI's Business Model
Greenwich LifeSciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which has completed Phase IIb clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.
| Sector & Industry | Healthcare / Biotechnology |
| Website | https://greenwichlifesciences.com |
| CEO (Chief Executive Officer) | Snehal S. Patel |
| Number of Employees | |
| IPO date | September 25, 2020 |
GLSI Latest News
|
|
|
|
|
|
|
|
|
|
| Contact | |
|---|---|
| Country | US |
| Address | Building 14 |
| City | Stafford |
| State | TX |
| Phone | 832 819 3232 |
| Zip Code | 77477 |
| Other Identifiers | |
| CIK | 0001799788 |
| ISIN | US3968791083 |
| CUSIP | 396879108 |
| Open | 9.97 |
| Previous Close | 9.88 |
| Volume | 31.42 Thou. |
| Average Volume | 70.98 Thou. |
| Day’s Range | 9.845 – 10.235 |
| 52 Week Range | 8.06-17.188 |
| MA (50) | 9.5868 |
| MA (200) | 11.84395 |
| Market Cap | 134.1 Mil. |
| Shares Out. | 13.37 Mil. |
| Earnings Date | Aug 12, 2025 |
| Beta | |
| Last Dividend | |
| EPS | |
| PE | |
